Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service debridement & negative-pressure wound therapy cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 989 | 192,883 | 46% |
| 2020 | 861 | 165,107 | 48% |
| 2021 | 879 | 177,315 | 51% |
| 2022 | 886 | 174,623 | 53% |
| 2023 | 863 | 174,810 | 55% |
| 2024 | 877 | 165,137 | 57% |
| 2025 from claims | – | 171,452 157,346–181,397 | 58% |
| 2026 forecast | – | 173,061 152,267–199,705 | 58% |
| 2027 forecast | – | 173,966 148,722–207,315 | 59% |
| 2028 forecast | – | 174,847 145,893–214,095 | 59% |
| 2029 forecast | – | 175,702 143,507–220,346 | 60% |
| 2030 forecast | – | 176,530 141,424–226,220 | 60% |
Surgical and selective debridement; NPWT, durable and disposable. Professional codes (what the surgeon bills): CPT 11042, 11043, 11044, 97597, 97605, 97606, 97607, 97608; the hospital bills MS-DRG 463, 464, 465.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 19% of the cases CMS names in New York; 323 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 5% inpatient hospital, 42% hospital outpatient, 54% office. The share outside the hospital has moved −5 pts since 2019.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~173,100 | ~8,300 | ~73,400 | ~91,400 |
| 2027 · ~174,000 | ~8,400 | ~74,400 | ~91,100 |
| 2028 · ~174,800 | ~8,500 | ~75,100 | ~91,200 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 52% (54% in 2025), hospital outpatient about 43% (42% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New Jersey | 590 | 129,243−0.9%/yr | −0.9%/yr | 118.7 | 49% | 147,900 in 2030+2.3%/yr |
| Pennsylvania | 643 | 120,771−1.4%/yr | −1.4%/yr | 84.3 | 52% | 123,700 in 2030+0.4%/yr |
| Massachusetts | 322 | 84,716+0.7%/yr | +0.7%/yr | 86.6 | 27% | 100,100 in 2030+2.8%/yr |
| Connecticut | 174 | 34,360−4.3%/yr | −4.3%/yr | 98.6 | 31% | 42,800 in 2030+3.7%/yr |
| Rhode Island | 58 | 12,053+0.5%/yr | +0.5%/yr | 125.0 | 32% | 14,900 in 2030+3.6%/yr |
| New Hampshire | 58 | 11,363−2.7%/yr | −2.7%/yr | 48.5 | 20% | 14,000 in 2030+3.5%/yr |
| Maine | 39 | 5,795−9.6%/yr | −9.6%/yr | 34.8 | 20% | 6,030 in 2030+0.7%/yr |
| Vermont | 18 | 1,868−6.3%/yr | −6.3%/yr | 15.9 | 33% | 3,090 in 2030+8.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Skin substitutes & wound grafts | 70 | 14,481+3.3%/yr | +3.3%/yr | 4.70.9× | 45% | 20,500 in 2030+5.9%/yr |
| Bone graft & orthobiologics | 21 | 796−5%/yr | −5%/yr | 0.40.9× | 1% | 810 in 2030+0.2%/yr |
Debridement & negative-pressure wound therapy in every state, and its device makers · Every procedure market in New York · Every state · Compare with New Jersey
Angiodynamics leads with 24% of company spending on these surgeons in 2025, −2 pts on 2024.
In 2025, 24 companies reported engagement with New York’s surgeons worth $1.0M in consulting, speaking, meals and travel tied to these products, about $1,155 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 10 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.